Benzinga | Aug 10, 2020 08:43AM EDT

Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $241

Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $235 to $241.